癌症研究
突变
克拉斯
比例危险模型
肺
危险系数
基因突变
作者
Fatemeh Ardeshir-Larijani,Priyanka Bhateja,Mary Beth Lipka,Neelesh Sharma,Pingfu Fu,Afshin Dowlati
标识
DOI:10.1016/j.cllc.2018.03.005
摘要
Abstract Background Mixed-lineage leukemia protein 2 (MLL2 or KMT2D) is a histone methyltransferase whose mutation has been associated with a poor prognosis in cancer. We compared the characteristics and significance of KMT2D alterations in non–small-cell lung cancer (NSCLC) with those in small cell lung cancer (SCLC). Patients and Methods Tumors from 194 NSCLC patients with locally advanced or advanced disease and 64 SCLC patients underwent targeted-exome sequencing. The association of KMT2D mutation with overall survival (OS) and progression-free survival (PFS) was measured using Kaplan-Meier methods and further evaluated using multivariable Cox proportional hazards regression model adjusting for known clinical prognostic features. Results The KMT2D mutation rate was 17.5% (34 of 194) in NSCLC. Patients with mutant KMT2D had significantly lower median OS (9.97 vs. 30.2 months; P Conclusion The KMT2D mutation was associated with reduced survival in NSCLC but not in SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI